

15 September 2025

APPOINTMENT OF DR FIONA COUSINS TO SCIENTIFIC ADVISORY BOARD

- EVE appoints Dr Fiona Cousins as inaugural member of its Scientific Advisory Board.
- Dr Cousins is a Senior Research Scientist at the Hudson Institute, specialising in endometrial biology and endometriosis.
- The SAB will provide strategic, scientific and clinical guidance across EVE's pipeline, with a focus on reproductive health, ahead of the commercial launch of Dyspro™, EVE's first proprietary prescription product.
- Reinforces EVE's commitment to evidence-based innovation in women's health.

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce the appointment of Dr Fiona Cousins as the first member of its newly established Scientific Advisory Board (**SAB**).

Dr Cousins is a Senior Research Scientist in The Ritchie Centre at the Hudson Institute of Medical Research, with more than a decade of experience in reproductive biology and women's health research. Her work focuses on inflammation and its role in endometriosis pathogenesis and identifying new therapeutic targets for endometriosis treatment. She holds a PhD in reproductive biology from the University of Edinburgh and has published extensively on endometrial regulation and dysfunction and endometriosis disease pathogenesis.

Dr Cousins' appointment provides EVE with internationally recognised expertise to help shape its R&D pipeline, with particular relevance to dysmenorrhoea and endometriosis, two of the most prevalent and under-addressed women's health conditions. This appointment comes at a pivotal time for EVE, with the Company on the verge of launching Dyspro™, its proprietary cannabinoid-based gummy formulation for the treatment of dysmenorrhoea (painful menstruation).

The SAB has been established to provide independent strategic, scientific and clinical guidance to the Board and executive management. Its role is to support the development and evaluation of evidence-based pharmaceutical and wellness products, with a focus on sexual and reproductive health, women's health, men's health and gut health. The SAB contributes expertise in research, clinical practice and product development to inform decisions on formulation strategy, target indications, regulatory positioning and consumer uptake.

EVE Executive Director and Chief Scientific Officer, Dr Stuart Gunzburg, said: "We are delighted to welcome Dr Fiona Cousins to our Scientific Advisory Board. Fiona's internationally recognised expertise in endometrial biology and endometriosis will be invaluable as we take Dyspro through commercial launch and advance our pipeline of women's health products. Her

appointment marks a milestone in strengthening the scientific foundation that underpins our strategy.”

Dr Fiona Cousins said: “I am pleased to join EVE’s Scientific Advisory Board as its inaugural member. The SAB has an important role in providing independent scientific advice to support EVE’s development programs. I look forward to contributing my expertise in women’s reproductive health to help shape the Company’s broader research and development efforts.”

Background on Dysmenorrhoea and Endometriosis

Dysmenorrhoea, or painful menstruation, is a prevalent condition among Australian women of reproductive age. A recent study found that 77% of women aged 18–44 reported experiencing bothersome menstrual symptoms, with the highest prevalence observed in the 18–24 age group. These symptoms significantly impact daily activities, with 44% of respondents reporting missed days of work or study.¹

The economic implications are substantial, with the annual burden of menstrual symptoms in Australia estimated at approximately AUD \$14.2 billion, primarily due to lost productivity.

In more severe cases, dysmenorrhoea (painful menstruation) may be associated with endometriosis, a chronic inflammatory condition estimated to affect up to 14% of reproductive-age women. A national survey found that the average annual cost of illness per woman with chronic pelvic pain (with or without endometriosis) ranged from US\$16,970 to US\$20,898, with 75–84% of costs attributed to lost productivity.²

Market Opportunity

Dysmenorrhoea and endometriosis are highly prevalent and under-addressed women’s health conditions, representing a substantial and growing global treatment market.

- The global dysmenorrhoea treatment market reached USD 10.9 billion in 2024 across the top seven pharmaceutical markets (US, EU4, UK, and Japan) and is forecast to grow at a CAGR of 5.73% to reach USD 20.0 billion by 2035.³
- In parallel, the Australian endometriosis treatment market is projected to reach USD 76.4 million by 2030, growing at a CAGR of 13% from 2025.⁴

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

¹ Mardon A.K. et al. *Problematic Periods Costing Young Women—The Impact of Menstrual Symptoms on Work and Study*, *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 2024.

<https://obgyn.onlinelibrary.wiley.com/doi/10.1111/ajgo.13926>

² Armour M. et al. *The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey*, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223316>

Figures in Armour et al. (2019) were originally reported in 2017 International dollars (Int \$), using purchasing power parity (PPP) to approximate US dollar values. These are expressed in USD here for clarity.

³ IMARC Group, *Dysmenorrhea Market Outlook 2025–2035*, www.imarcgroup.com/dysmenorrhea-market

⁴ Grand View Research, *Australia Endometriosis Treatment Market Outlook*, www.grandviewresearch.com/horizon/outlook/endometriosis-treatment-market/australia